Abrysvo powder and solvent for solution for injection

Abrysvo is indicated for:

• Active immunisation of pregnant individuals to protect infants from birth through 6 months of age against lower respiratory tract disease caused by respiratory syncytial virus (RSV). See sections 4.2 and 5.1.

• Active immunisation for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.

• Active immunisation for the prevention of lower respiratory tract disease caused by RSV in individuals 18 through 59 years of age who are at increased risk for lower respiratory tract disease caused by RSV.

The use of this vaccine should be in accordance with official recommendations.

Posology

Pregnant individuals

A single dose of 0.5 mL should be administered between weeks 28 and 36 of gestation (see sections 4.4, 4.6 and 5.1).

Individuals 18 years of age and older

A single dose of 0.5 mL should be administered.

The need for revaccination has not been established.

Immunocompromised individuals

A single dose of 0.5 mL should be administered. The need for a second dose has not been established (see section 5.1).

Paediatric population

The safety and efficacy of Abrysvo in children (from birth to less than 18 years of age) have not yet been established. Limited data are available in pregnant adolescents and their infants (see section 5.1).

Method of administration

Abrysvo is for intramuscular injection into the deltoid region of the upper arm.

The vaccine should not be mixed with any other vaccines or medicinal products.

For instructions on reconstitution and handling of the medicinal product before administration, see section 6.6.

Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.

Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

Hypersensitivity and anaphylaxis

Appropriate medical treatment and supervision should always be readily available in case of an anaphylactic event following the administration of the vaccine.

Anxiety-related reactions

Anxiety-related reactions, including vasovagal reactions (syncope), hyperventilation or stress-related reactions may occur in association with vaccination as a psychogenic response to the needle injection. It is important that procedures are in place to avoid injury from fainting.

Concurrent illness

Vaccination should be postponed in individuals suffering from an acute febrile illness. However, the presence of a minor infection, such as a cold, should not result in the deferral of vaccination.

Thrombocytopenia and coagulation disorders

Abrysvo should be given with caution to individuals with thrombocytopenia or any coagulation disorder since bleeding or bruising may occur following an intramuscular administration to these individuals.

Immunocompromised individuals

Safety and immunogenicity have been assessed in immunocompromised individuals, including those receiving immunosuppressant therapy (see sections 4.8 and 5.1). The efficacy of Abrysvo may be lower in immunosuppressed individuals.

Individuals less than 28 weeks of gestation

Abrysvo has not been studied in pregnant individuals less than 24 weeks of gestation and should not be used in pregnant individuals less than 28 weeks of gestation (see sections 4.2, 4.6 and 5.1).

Limitations of vaccine effectiveness

As with any vaccine, a protective immune response may not be elicited after vaccination.

Guillain-Barré Syndrome

Guillain-Barré syndrome has been reported rarely following vaccination with Abrysvo in individuals ≥ 60 years (see section 4.8).

Healthcare professionals should be attentive to signs and symptoms of Guillain-Barré syndrome in all Abrysvo recipients to ensure correct diagnosis, in order to initiate adequate supportive care and treatment, and rule out other causes.

Excipients

This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially 'sodium‑free'.

Abrysvo contains polysorbate 80. Polysorbate 80 may cause hypersensitivity reactions.

Abrysvo can be administered concomitantly with:
 • seasonal influenza vaccines, either standard dose adjuvanted or high dose unadjuvanted.
 • COVID-19 mRNA vaccines, with or without high dose unadjuvanted influenza vaccine administered concomitantly.

A minimum interval of two weeks is recommended between administration of Abrysvo and administration of a tetanus, diphtheria and acellular pertussis vaccine (Tdap). There were no safety concerns when Abrysvo was co‑administered with Tdap in healthy non‑pregnant women. Immune responses to RSV A, RSV B, diphtheria and tetanus on co‑administration were non-inferior to those after separate administration. However, the immune responses to the pertussis components were lower on co‑administration compared to separate administration and did not meet the criteria for non‑inferiority. The clinical relevance of this finding is unknown.

Data on concomitant administration of Abrysvo and vaccines other than those listed is not available.

Pregnancy

Data on pregnant women (more than 4 000 exposed outcomes) indicate no malformative nor feto/neonatal toxicity.

Results from animal studies with Abrysvo do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).

In a phase 3 study (Study 1), maternal adverse events reported within 1 month after vaccination were similar in the Abrysvo group (14%) and the placebo group (13%).

No safety signals were detected in infants up to 24 months of age. The incidences of adverse events reported within 1 month after birth in infants were similar in the Abrysvo group (38%) and the placebo group (35%). Major birth outcomes assessed in the Abrysvo group compared to placebo included premature birth (207 (6%) and 172 (5%), respectively), low birth weight (186 (5%) and 158 (4%), respectively) and congenital anomalies (205 (6%) and 245 (7%), respectively). As a precautionary measure until more data are available, Abrysvo should be administered to pregnant individuals between weeks 28 and 36 of gestation to minimise any potential risk of extremely premature birth (see section 4.2).

Breast-feeding

It is unknown whether Abrysvo is excreted in human milk. No adverse effects of Abrysvo have been shown in breastfed newborns of vaccinated mothers.

Fertility

No human data on the effect of Abrysvo on fertility are available.

Animal studies do not indicate direct or indirect harmful effects with respect to female fertility (see section 5.3).

Abrysvo has no or negligible influence on the ability to drive and use machines.

Summary of the safety profile

Pregnant individuals

In pregnant women at 24-36 weeks of gestation the most frequently reported adverse reactions were vaccination site pain (41%), headache (31%) and myalgia (27%). The majority of local and systemic reactions in maternal participants were mild to moderate in severity and resolved within 2-3 days of onset.

Individuals 18 years of age and older

In individuals 18 years of age and older the most frequently reported adverse reactions were fatigue (23%), headache (20%), vaccination site pain (19%) and myalgia (16%). The majority of reactions were mild to moderate in severity and resolved within 1‑2 days of onset.

Tabulated list of adverse reactions

The safety of administering a single dose of Abrysvo to pregnant women at 24-36 weeks of gestation (n=3 698) and to individuals 18 years of age and older (n=20 275) was evaluated in clinical trials.

Adverse reactions are listed according to the following frequency categories:

Very common (≥1/10);

Common (≥1/100 to <1/10);

Uncommon (≥1/1 000 to <1/100);

Rare (≥1/10 000 to <1/1 000);

Very rare (<1/10 000);

Not known (cannot be estimated from the available data).

Adverse reactions reported are listed per system organ class, in decreasing order of seriousness.

Table 1 Adverse reactions following administration of Abrysvo

^aFrequency reported in individuals 60 years of age and older

Special populations

Immunocompromised individuals 18 years of age and older

Reactogenicity was consistent with the known profile of Abrysvo. There were no unexpected safety findings.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Overdose with Abrysvo is unlikely due to its single dose presentation.

There is no specific treatment for an overdose with Abrysvo. In the event of an overdose, the individual should be monitored and provided with symptomatic treatment as appropriate.

Pharmacotherapeutic group: Vaccines, other viral vaccines; ATC code: J07BX05

Mechanism of action

Abrysvo contains two recombinant stabilised RSV prefusion F antigens representing subgroups RSV‑A and RSV‑B. Prefusion F is the primary target of neutralising antibodies that block RSV infection. Following intramuscular administration, the prefusion F antigens elicit an immune response, which protects against RSV‑associated lower respiratory tract disease (LRTD).

In infants born to mothers who were vaccinated with Abrysvo between weeks 24 and 36 of gestation, protection against RSV-associated LRTD is due to transplacental transfer of RSV neutralising antibodies. Adults 18 years of age and older are protected by active immunisation.

Clinical efficacy

Infants from birth through 6 months of age by active immunisation of pregnant individuals

Study 1 was a phase 3, multicentre, randomised (1:1), double-blind, placebo‑controlled study to assess the efficacy of a single dose of Abrysvo in the prevention of RSV‑associated LRTD in infants born to pregnant individuals vaccinated between weeks 24 and 36 of gestation. The need for revaccination with subsequent pregnancies has not been established.

RSV-associated LRTD was defined as a medically attended visit in individuals with a reverse transcription-polymerase chain reaction (RT-PCR) confirmation of RSV and with one or more of the following respiratory symptoms: fast breathing, low oxygen saturation (SpO₂ <95%) and chest wall indrawing. Severe RSV-associated LRTD was defined as RSV‑associated LRTD that additionally met at least one of the following criteria: very fast breathing, low oxygen saturation (SpO₂ <93%), high-flow oxygen supplementation via nasal cannula or mechanical ventilation, ICU admission for >4 hours and/or failure to respond/unconscious.

In this study, 3 711 pregnant individuals with uncomplicated, singleton pregnancies were randomised to the Abrysvo group and 3 709 to placebo.

Vaccine efficacy (VE) was defined as the relative risk reduction of the endpoint in the Abrysvo group compared to the placebo group for infants born to pregnant individuals who received the assigned intervention. At the primary analysis, there were two primary efficacy endpoints, assessed in parallel, severe RSV‑positive medically attended LRTD and RSV‑positive medically attended LRTD, occurring within 90, 120, 150 or 180 days after birth.

Of the pregnant women who received Abrysvo, 65% were White, 20% were Black or African American and 29% were Hispanic/Latino. The median age was 29 years (range 16‑45 years); 0.2% of participants were under 18 years of age and 4.3% were under 20 years of age. The median gestational age at vaccination was 31 weeks and 2 days (range 24 weeks and 0 days to 36 weeks and 4 days). The median infant gestational age at birth was 39 weeks and 1 day (range 27 weeks and 3 days to 43 weeks and 6 days).

Vaccine efficacy is presented in Tables 2, 3, 4 and 5.

Table 2 Vaccine efficacy of Abrysvo against severe medically attended LRTD caused by RSV in infants from birth through 6 months of age by active immunisation of pregnant individuals – Study 1

CI = confidence interval; VE = vaccine efficacy

^a 99.5% CI at 90 days; 97.58% CI at later intervals

Table 3 Vaccine efficacy of Abrysvo against medically attended LRTD caused by RSV in infants from birth through 6 months of age by active immunisation of pregnant individuals – Study 1

CI = confidence interval; VE = vaccine efficacy

^a 99.5% CI at 90 days; 97.58% CI at later intervals

Table 4 Vaccine efficacy of Abrysvo against severe medically attended LRTD caused by RSV in infants from birth through 6 months of age by active immunisation of pregnant individuals between weeks 28 and 36 of gestation – Study 1^a

CI = confidence interval; VE = vaccine efficacy

^a This post-hoc descriptive subgroup analysis was not controlled for multiple comparisons

^b 95% CI

Table 5 Vaccine efficacy of Abrysvo against medically attended LRTD caused by RSV in infants from birth through 6 months of age by active immunisation of pregnant individuals between weeks 28 and 36 of gestation – Study 1^a

CI = confidence interval; VE = vaccine efficacy

^a This post-hoc descriptive subgroup analysis was not controlled for multiple comparisons

^b 95% CI

Individuals 60 years of age and older

Study 2 was a phase 3, multicentre, randomised, double‑blind, placebo-controlled study to assess the efficacy of Abrysvo in the prevention of RSV‑associated LRTD in individuals 60 years of age and older.

RSV-associated LRTD was defined as RT‑PCR confirmed RSV disease with two or more or three or more of the following respiratory symptoms within 7 days of symptom onset and lasting more than 1 day during the same illness: new or increased cough, wheezing, sputum production, shortness of breath or tachypnoea (≥25 breaths/min or 15% increase from resting baseline).

Participants were randomised (1:1) to receive Abrysvo (n=18 487) or placebo (n=18 479). Enrollment was stratified by age 60-69 years (63%), 70-79 years (32%) and ≥80 years (5%). Subjects with stable chronic underlying conditions were eligible for this study and 52% of participants had at least 1 prespecified condition; 16% of participants were enrolled with stable chronic cardiopulmonary conditions such as asthma (9%), chronic obstructive pulmonary disease (7%) or congestive heart failure (2%). Immunocompromised individuals were ineligible.

The primary objective was assessment of vaccine efficacy (VE), defined as the relative risk reduction of first episode of RSV-associated LRTD in the Abrysvo group compared to the placebo group in the first RSV season.

Of the participants who received Abrysvo, 51% were male and 80% were White, 12% were Black or African American and 42% were Hispanic/Latino. The median age of participants was 67 years (range 59‑95 years).

At the end of the first RSV season the analysis demonstrated statistically significant efficacy for Abrysvo for reduction of RSV-associated LRTD with ≥2 symptoms and with ≥3 symptoms.

Vaccine efficacy information at the end of the first RSV season (median follow‑up time 7.4 months) is presented in Table 6.

Table 6 Vaccine efficacy of Abrysvo against RSV disease - active immunisation of individuals 60 years of age and older – Study 2

CI – confidence interval; RSV – respiratory syncytial virus; VE – vaccine efficacy

N = number of participants; n = number of cases

^a In an exploratory analysis in RSV subgroup A (Abrysvo n=3, placebo n=16) VE was 81.3% (CI 34.5, 96.5); and in RSV subgroup B (Abrysvo n=12, placebo n=26) VE was 53.8% (CI 5.2, 78.8).

^b In an exploratory analysis in RSV subgroup A (Abrysvo n=1, placebo n=5) VE was 80.0% (CI -78.7, 99.6); and in RSV subgroup B (Abrysvo n=1, placebo n=12) VE was 91.7% (CI 43.7, 99.8).

Vaccine efficacy in the subgroup of participants 80 years of age and older (995 and 981 participants in the Abrysvo and placebo groups, respectively) cannot be concluded due to the low number of total cases accrued (7 cases of RSV-associated LRTD with ≥2 symptoms and 3 cases of RSV-associated LRTD with ≥3 symptoms).

Efficacy against RSV-associated lower respiratory tract disease over 2 RSV seasons in individuals 60 years of age and older

Across 2 RSV seasons with median follow-up time of 16.4 months, VE against RSV‑associated LRTD with ≥2 symptoms was 58.8% (95% CI 43.0, 70.6; 54 cases in the Abrysvo group and 131 cases in the placebo group) and with ≥3 symptoms was 81.5% (95% CI 63.3, 91.6; 10 cases in the Abrysvo group and 54 cases in the placebo group). VE against RSV‑associated LRTD caused by RSV-A and RSV-B was 66.3% (95% CI 47.2, 79.0) and 50.0% (95% CI 18.5, 70.0) for cases with ≥2 LRTD symptoms respectively, and 80.6% (95% CI 52.9, 93.4) and 86.4% (95% CI 54.6, 97.4) for cases with ≥3 LRTD symptoms, respectively.

Across 2 RSV seasons, subgroup analyses of VE by age and significant underlying conditions were consistent with VE at the end of the first RSV season and support consistent VE across different age and risk groups.

Immunogenicity in individuals 18 through 59 years of age considered to be at increased risk of LRTD caused by RSV.

Study 3 was a Phase 3, multicentre, randomised, double-blind, placebo-controlled study to assess the safety and immunogenicity of Abrysvo in individuals 18 through 59 years of age considered to be at high risk of developing severe LRTD caused by RSV. Study 3 enrolled individuals who had chronic pulmonary (including asthma), cardiovascular (excluding isolated hypertension), renal, hepatic, neurologic, haematologic or metabolic disorders (including diabetes mellitus and hyper/hypothyroidism). Participants were randomised (2:1) to receive a single dose of Abrysvo (n=437) or placebo (n=217).

Demographic characteristics in study 3 were generally similar with regard to age, race and ethnicity among participants who received Abrysvo and those who received placebo. Fifty-three percent (53%) were 18 to 49 years and 47% were 50 to 59 years. The vaccine and placebo groups were similar with regards to having at least one prespecified medical condition, which included 53% with ≥1 chronic pulmonary condition, 8% with ≥1 cardiovascular condition, 42% with diabetes and 31% ≥1 other disease (liver, renal, neurologic, haematologic or other metabolic disease).

Vaccine efficacy in individuals 18 through 59 years of age is inferred by immunobridging to study 2 where vaccine efficacy was demonstrated in individuals 60 years of age and older. The non‑inferiority criteria were met for high risk individuals 18 through 59 years of age compared to a randomly selected immunogenicity subset (external control group) of individuals ≥60 years of age from study 2 for the ratio of RSV neutralising geometric mean titres (GMTs) by the lower bounds of the 2‑sided 95% CIs >0.667 (1.5‑fold non‑inferiority margin), and for the difference in seroresponse rates by the lower bounds of the 2‑sided 95% CIs > -10% for both RSV A and RSV B.

Table 7 Comparison of model adjusted RSV neutralising titre GMTs at 1 month after vaccination with Abrysvo, 18 through 59 years at high risk (Study 3) versus 60 years and older (Study 2)

CI – confidence interval; GMR – geometric mean ratio; GMT – geometric mean titre

Table 8 Comparison of RSV neutralising titre seroresponse rates 1 month after vaccination with Abrysvo, 18 through 59 years at high risk (Study 3) versus 60 years and older (Study 2)

CI – confidence interval

Immunogenicity in immunocompromised individuals 18 years of age and older

Study 4 (C3671023 Substudy B) was a Phase 3, single-arm, open-label, multicentre study to assess the safety and immunogenicity of Abrysvo in immunocompromised individuals ≥18 years of age. Participants had history of a solid organ transplant (kidney, liver, lung or heart) at least 3 months prior to enrollment; end stage renal disease and on haemodialysis; autoimmune inflammatory disorders with active immunomodulator therapy; or advanced non-small cell lung cancer and receiving active immunomodulator therapy. Participants received 2 doses of Abrysvo with an interval of 1 month.

A single dose of Abrysvo was sufficient to elicit robust neutralising responses approximately 8- or 9- fold above baseline against RSV A and RSV B in participants ≥18 years of age with immunocompromising conditions (n=188). Responses did not further increase with a second dose of Abrysvo 1 month after the first dose.

Paediatric population

The licensing authority has deferred the obligation to submit the results of studies with Abrysvo in children from 2 to less than 18 years of age in prevention of lower respiratory tract disease caused by RSV (see section 4.2 for information on paediatric use).

Not applicable.

Non-clinical data reveal no special hazard for humans based on conventional studies of repeated dose toxicity and toxicity to reproduction and development.

Powder

Trometamol

Trometamol hydrochloride

Sucrose

Mannitol (E421)

Polysorbate 80 (E433)

Sodium chloride

Hydrochloric acid (for pH adjustment)

Solvent

Water for injections

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

4 years

The unopened vial is stable for 5 days when stored at temperatures from 8°C to 30°C. At the end of this period Abrysvo should be used or discarded. This information is used to guide healthcare professionals in case of temporary temperature excursions only.

After reconstitution

Abrysvo should be administered immediately after reconstitution or within 4 hours if stored between 15°C and 30°C. Do not freeze.

Chemical and physical in-use stability has been demonstrated for 4 hours between 15°C and 30°C. From a microbiological point of view, the product should be used immediately. If not used immediately, in‑use storage times and conditions prior to use are the responsibility of the user.

Store in a refrigerator (2°C - 8°C).

Do not freeze. Discard if the carton has been frozen.

For storage conditions after reconstitution of the medicinal product, see section 6.3.

Vial of antigens for Abrysvo (powder) and pre‑filled syringe of solvent

Powder for 1 dose in a vial (type 1 glass or equivalent) with a stopper (synthetic bromobutyl rubber or synthetic chlorobutyl rubber) and a flip off cap

Solvent for 1 dose in a pre-filled syringe (type 1 glass) with a stopper (synthetic chlorobutyl rubber) and a tip cap (synthetic isoprene/bromobutyl blend rubber)

Vial adaptor

Vial of antigens for Abrysvo (powder) and vial of solvent

Powder for 1 dose in a vial (type 1 glass or equivalent) with a stopper (synthetic bromobutyl rubber or synthetic chlorobutyl rubber) and a flip off cap

Solvent for 1 dose in a vial (type 1 glass or equivalent) with a stopper (synthetic bromobutyl rubber) and a flip off cap

Pack sizes

Pack containing 1 vial of powder (antigens), 1 pre-filled syringe of solvent, 1 vial adaptor with 1 needle or without needles (1 dose pack).

Pack containing 5 vials of powder (antigens), 5 pre-filled syringes of solvent, 5 vial adaptors with 5 needles or without needles (5 dose pack).

Pack containing 10 vials of powder (antigens), 10 pre-filled syringes of solvent, 10 vial adaptors with 10 needles or without needles (10 dose pack).

Pack containing 5 vials of powder (antigens) and 5 vials of solvent (5 dose pack).

Pack containing 10 vials of powder (antigens) and 10 vials of solvent (10 dose pack).

Not all pack sizes may be marketed.

For use of vial of antigens for Abrysvo (powder), pre‑filled syringe of solvent and vial adaptor

Abrysvo must be reconstituted prior to administration by adding the entire contents of the pre‑filled syringe of solvent to the vial containing the powder using the vial adaptor.

The vaccine must be reconstituted only with the solvent provided.

Preparation for administration

The prepared vaccine is a clear and colourless solution. Visually inspect the vaccine for large particulate matter and discolouration prior to administration. Do not use if large particulate matter or discolouration is found.

For use of vial of antigens for Abrysvo (powder) and vial of solvent

The vial containing antigens for Abrysvo (powder) must be reconstituted only with the vial of solvent provided to form Abrysvo.

Preparation for administration

1. Using a sterile needle and sterile syringe, withdraw the entire contents of the vial containing the solvent and inject the entire contents of the syringe into the vial containing the powder.
2. Gently swirl the vial in a circular motion until the powder is completely dissolved. Do not shake.
3. Withdraw 0.5 mL from the vial containing the reconstituted vaccine.

The prepared vaccine is a clear and colourless solution. Visually inspect the vaccine for large particulate matter and discolouration prior to administration. Do not use if large particulate matter or discolouration is found.

Disposal

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.